I D
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chementator Briefs
Caprolactam Genomatica (San Diego, Calif.; www.genomatica.com) recently announced the production…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORTFACTS AT YOUR FINGERTIPSTECHNOLOGY PROFILESOLIDS PROCESSINGEQUIPMENT & SERVICESFOCUSNEW PRODUCTS + Show More

Comment Business & Economics

Wound dressing

By Chemical Engineering |

Last Month, Bayer Innovation GmbH (Leverkusen, Germany; edlinks.chemengonline.com/6896-551) started a pilot plant for producing a bioresorbable wound dressing in sufficient quantities to enable clinical trials to be carried out. Once the clinical phase of development is sucessfully completed, regulatory approval in the first market is expected in 2010. The dressing is based on silica gel fibers, which form a scaffold around which skin cells can grow, and is then decomposed by the body during the wound-healing process. The basic technology was first discovered ten years ago by the Fraunhofer Institute for Silicate Research (Würzburg), and subsequently developed by Bayer Innovation.
Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Improving chemical production processes with IIoT and AI technologies
New filtration technology for highly corrosive media
PTA production: Lowering OPEX without compromising on quality
Sure that zero means zero in your zero-liquid discharge (ZLD) process?
How separation processes profit from Industrial Internet of Things (IIoT) solutions

View More